Loading
ImmuneBro Therapeutics in Chicago makes off-the-shelf immune cell treatments from healthy donors' T cells, combined with a T-cell engager, without gene editing. Its lead product, IBT1116, is being prepared for trials in B-cell cancers.
ImmuneBro Therapeutics develops allogeneic T cell products from healthy donor T cells that integrate T cell therapy with a T cell engager, avoiding genome editing and CAR engineering, according to the company. Its one lead asset, IBT1116, is at the IND-enabling stage for relapsed or refractory B-cell malignancies and relapse after CD19 CAR-T therapy. In fiscal year 2026 NCI awarded it USD 1,351,438 under SBIR award 2R44CA281523-02 for its engager T cell approach to off-the-shelf T cell therapy.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR award (R44) 2R44CA281523-02: Engager T cell: A Simple Solution for "Off-the-shelf" T Cell Therapy for Cancer | 2026 | $1M | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
IBT1116 is an experimental off-the-shelf immune cell treatment from ImmuneBro Therapeutics for B-cell cancers, including after CAR-T relapse. It has not yet entered trials.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/